S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.55
+1.87
+11.21%
ONCO · Onconetix, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$0.43
+0.03
(+6.55%)
● At close: October 21 at 4:00:00 PM EDT
$0.44
+0.01
(+1.79%)
Pre-Market:
4:01:42 AM EDT
DAY'S RANGE
$0.43
$0.42
$0.45
52-WEEK RANGE
$0.43
$0.38
$200.00
What's happening
- ONCO is up 6.55% today, trading at $0.43. — Live quote
- It's trading within 3% of its 52-week low ($0.38). (Finnhub fundamentals)
- Volume today (2,825) is well below its 3-month average of 2,333,340. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 3
Sell 1
Strong sell 2
Aggregate ratings for 2024-05-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ONCO
-99.48%
vs S&P 500
-112.26%
1-YEAR RETURN
ONCO
-99.76%
vs S&P 500
-114.32%
6-MONTH RETURN
ONCO
-94.65%
3-MONTH RETURN
ONCO
-54.32%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2025-04-26 (Q1 2025)
$0.25
Est. $—
2023-10-26 (Q3 2023)
$-45900.00
Est. $-32946.00
MISS -39.3%
2023-07-26 (Q2 2023)
$-35700.00
Est. $-26010.00
MISS -37.3%
2023-04-26 (Q1 2023)
$-30600.00
Est. $-36414.00
BEAT +16.0%
Valuation Measures & Ratios
Enterprise Value4-$3.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3.30
Price / Book70.31
EV4 / Revenue-5.67
EV4 / EBITDA—
Profit Margin-1578.77%
Operating Margin-3389.15%
Return on Equity (ROE8)-91.94%
Return on Assets (ROA9)-53.76%
Avg Volume (3M)2,333,340
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.6M | $9.4M | $210.1M | $2.4M | $12.3M |
| P/E | -0.14 | -0.39 | -8.93 | -0.08 | -0.32 |
| Price/Sales | 5.79 | 17.61 | 228.72 | 1.82 | 6.41 |
| Price/Book | 0.19 | 0.80 | — | 0.41 | 3.07 |
| EV/Revenue | 5.79 | 17.61 | 228.72 | 1.82 | 6.41 |
| ROE | -135.41% | -203.61% | — | -491.60% | -946.67% |
| ROA | -111.03% | -161.25% | -119.57% | -151.96% | -201.32% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short489,621
Change from Prior Settlement+261.82%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -83.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -1578.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -99.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ONCO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.1K | $21.5K | $303.7K | $106.5K | $101.6K | $406.9K | $704.8K | $700.4K |
| Gross profit | $4.3K | -$1.7K | $268.9K | $70.5K | $45.8K | $105.4K | $100.7K | $189.0K |
| Operating income | -$2.7M | -$10.2M | -$2.1M | -$1.9M | -$12.6M | -$2.6M | -$13.6M | -$11.1M |
| Net income | -$2.9M | -$4.2M | -$8.8M | -$2.4M | -$8.5M | -$3.8M | -$14.3M | -$11.1M |
| EPS (diluted) | $-1.28 | $-6.71 | $-6.25 | $-237.91 | $-227.25 | $-249.08 | $-2191.59 | $-20.08 |
| EPS (basic) | $-1.28 | $-6.71 | $-6.25 | $-237.91 | $-227.25 | $-249.08 | $-2191.59 | $-20.08 |
| Operating margin | -$16.0K | -$47.7K | -$681 | -$1.8K | -$12.4K | -$650 | -$1.9K | -$1.6K |
| Net margin | -$16.7K | -$19.6K | -$2.9K | -$2.2K | -$8.4K | -$941 | -$2.0K | -$1.6K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $16.4M | $14.8M | $24.9M | $19.7M | $19.1M | $18.8M | $28.2M | $61.9M |
| Total liabilities | $3.0M | $3.1M | $9.2M | $16.3M | $12.8M | $14.3M | $18.6M | $20.9M |
| Stockholders' equity | $13.5M | $11.7M | $15.8M | — | $5.9M | $4.0M | $8.5M | $33.9M |
| Total current assets | $6.5M | $4.3M | $6.1M | $1.3M | $930.5K | $2.4M | $950.3K | $1.0M |
| Total current liabilities | $2.9M | $3.1M | $9.1M | $16.3M | $12.7M | $14.0M | $18.3M | $17.4M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Accounts receivable | $2.4K | $43.7K | $296.9K | $2.6K | $12.2K | $16.3K | $25.7K | $98.0K |
| Inventory | $210.4K | $137.6K | $150.0K | $151.6K | $153.1K | $155.7K | $64.1K | $121.8K |
| Property, plant & equipment | $28.7K | $31.5K | $37.1K | $40.4K | $43.8K | $55.8K | $62.9K | $69.3K |
| Goodwill | $9.6M | $10.2M | $18.5M | $18.2M | $18.1M | $16.2M | $27.0M | $38.9M |
| Intangible assets | — | — | — | — | — | — | — | $21.4M |
| Accounts payable | $1.8M | $1.5M | $1.8M | $1.8M | $2.6M | $2.6M | $3.8M | $4.1M |
| Accrued liabilities | $249.6K | $279.1K | $341.9K | $476.3K | $895.0K | $1.2M | $889.0K | $1.3M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $38 | $27 | $3 | $15 | $10 | $368 | $1 | $83 |
| Retained earnings | -$138.3M | -$135.4M | -$131.2M | -$136.9M | -$128.1M | -$125.4M | -$115.7M | -$86.0M |
| Accumulated other comprehensive income (loss) | -$568.7K | -$441.2K | -$231.0K | -$547.1K | -$385.3K | -$2.6M | -$2.7M | $1.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$2.1M | -$3.1M | -$3.2M | -$1.4M | -$2.0M | -$917.6K | -$1.1M |
| Investing cash flow | — | — | — | — | — | — | -$3.9K | -$2.3K |
| Financing cash flow | $4.2M | $631.8K | $6.5M | $4.3M | $744.6K | $2.9M | $1.3M | $578.6K |
| Free cash flow | — | — | — | — | — | — | -$921.5K | -$1.1M |
| Capital expenditures | — | — | — | — | — | — | $3.9K | $2.3K |
| Depreciation & amortization | — | — | — | — | — | — | — | $204.0K |
| Share-based compensation | $7.4K | $22.3K | $4.2K | $9.8K | $31.0K | $29.3K | $340.4K | $46.4K |
| Deferred income taxes | — | — | — | — | — | — | -$918.0K | -$56.4K |
| Change in accounts receivable | -$41.5K | -$270.7K | $293.9K | -$9.6K | -$6.2K | -$9.5K | -$67.6K | -$80.6K |
| Change in inventory | $76.2K | -$11.7K | -$462 | $1.4K | -$18.3K | $91.0K | -$50.8K | -$46.0K |
| Change in accounts payable | $312.1K | -$224.8K | -$45.7K | -$775.2K | -$11.4K | -$261.4K | -$235.0K | $946.6K |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $815.4K | $2.5M | $58.5K | — | — |
| Gross profit | $632.9K | $1.1M | -$1.1M | — | — |
| Operating income | -$17.9M | -$56.5M | -$36.0M | -$13.5M | -$3.4M |
| Net income | -$14.0M | -$58.7M | -$37.4M | -$13.4M | -$3.4M |
| EPS (diluted) | $-16.56 | $-1823.39 | $-87.45 | $-1.10 | $-1.26 |
| EPS (basic) | $-16.56 | $-1823.39 | $-87.45 | $-1.10 | $-1.26 |
| Operating margin | -$2.2K | -$2.2K | -$61.6K | — | — |
| Net margin | -$1.7K | -$2.3K | -$64.0K | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $24.9M | $28.2M | $87.5M | $26.3M | $3.1M |
| Total liabilities | $9.2M | $18.6M | $21.9M | $3.9M | $1.6M |
| Stockholders' equity | — | $8.5M | -$5.6M | $22.4M | $1.4M |
| Total current assets | $6.1M | $950.3K | $5.8M | $26.3M | $3.1M |
| Total current liabilities | $9.1M | $18.3M | $17.2M | $3.9M | $1.6M |
| Cash & equivalents | — | — | — | $25.8M | $1.9M |
| Accounts receivable | $296.9K | $25.7K | $149.7K | — | — |
| Inventory | $150.0K | $64.1K | $364.1K | — | — |
| Property, plant & equipment | $37.1K | $62.9K | $60.7K | $14.1K | $11.5K |
| Goodwill | $18.5M | $27.0M | $55.7M | — | — |
| Intangible assets | — | — | $25.4M | — | — |
| Accounts payable | $1.8M | $3.8M | $5.3M | $1.5M | $582.6K |
| Accrued liabilities | $341.9K | $889.0K | $2.2M | $2.4M | $1.1M |
| Other current liabilities | — | — | $866.6K | — | — |
| Common stock & paid-in capital | $15 | $1 | $6 | $157 | $32 |
| Retained earnings | -$131.2M | -$115.7M | -$56.8M | -$19.4M | -$6.0M |
| Accumulated other comprehensive income (loss) | -$231.0K | -$2.7M | $2.4M | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.7M | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Investing cash flow | — | -$28.5K | -$8.6M | -$32.7K | -$1.9K |
| Financing cash flow | $14.5M | $6.7M | $1.0M | $32.5M | -$334.2K |
| Free cash flow | — | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Capital expenditures | — | $28.5K | $3.3K | $9.3K | $1.9K |
| Depreciation & amortization | — | — | $43.9K | $6.8K | — |
| Share-based compensation | $74.3K | $438.7K | $329.8K | $2.0M | $130.1K |
| Deferred income taxes | — | -$1.0M | -$12.6K | — | — |
| Change in accounts receivable | $268.7K | -$116.7K | $62.3K | — | — |
| Change in inventory | $73.7K | $62.3K | $315.8K | — | — |
| Change in accounts payable | -$1.1M | -$1.5M | $3.4M | $1.1M | $336.7K |
| Share repurchases | — | — | — | $566.8K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ONCO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-05-09 to 2026-04-21
Recent transactions
- Most recent: HRT FINANCIAL LP (10% owner) — Open market sale of 49,710 shares on 2026-04-21.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| HRT FINANCIAL LP | 10% owner | Open market sale | 2026-04-21 | 49,710 |
| Oakley Andrew John | Director | Other acquisition/disposition | 2025-08-15 | 20 |
| Tarsh Simon | Director | Other acquisition/disposition | 2025-08-15 | 39 |
| Meier Thomas | Director | Other acquisition/disposition | 2025-08-15 | 39 |
| Ramdeen Timothy R. | Director | Other acquisition/disposition | 2025-08-15 | 39 |
| Altos Venture AG | Reporting person | Other acquisition/disposition | 2025-07-14 | 241,514 |
| Schiess Ralph | Interim CEO, CSO | Grant / award | 2024-12-20 | 177,462 |
| Bruhlmann Christian | Chief Strategy Officer | Grant / award | 2024-12-20 | 177,462 |
| SINGH AJIT | Director | Grant / award | 2024-09-26 | 3,318 |
| SAPIRSTEIN JAMES | Director | Grant / award | 2024-09-26 | 3,318 |
| Jeremic Vuk | Director | Grant / award | 2023-05-31 | 6,360 |
| Hernandez Joseph | CEO | Grant / award | 2023-05-09 | 150,000 |
| Garfield Jon | Chief Financial Officer | Grant / award | 2023-05-09 | 100,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-21 | HRT FINANCIAL LP | 10% owner | Open market sale | 49,710 | $0.69 |
| 2026-04-20 | HRT FINANCIAL LP | 10% owner | Open market sale | 94,462 | $0.75 |
| 2026-04-17 | HRT FINANCIAL LP | 10% owner | Open market purchase | 34,636 | $0.73 |
| 2026-04-16 | HRT FINANCIAL LP | 10% owner | Open market sale | 53,867 | $0.73 |
| 2026-04-15 | HRT FINANCIAL LP | 10% owner | Open market purchase | 92,554 | $0.76 |
| 2026-04-14 | HRT FINANCIAL LP | 10% owner | Open market purchase | 74,350 | $0.77 |
| 2025-08-15 | Oakley Andrew John | Director | Other acquisition/disposition | 20 | $0.00 |
| 2025-08-15 | Oakley Andrew John | Director | Grant / award | 618 | $0.00 |
| 2025-08-15 | Tarsh Simon | Director | Other acquisition/disposition | 39 | $0.00 |
| 2025-08-15 | Tarsh Simon | Director | Grant / award | 618 | $0.00 |
| 2025-08-15 | Meier Thomas | Director | Other acquisition/disposition | 39 | $0.00 |
| 2025-08-15 | Meier Thomas | Director | Grant / award | 618 | $0.00 |
| 2025-08-15 | Ramdeen Timothy R. | Director | Other acquisition/disposition | 39 | $0.00 |
| 2025-08-15 | Ramdeen Timothy R. | Director | Grant / award | 618 | $0.00 |
| 2025-07-14 | Altos Venture AG | Reporting person | Other acquisition/disposition | 241,514 | — |
| 2025-03-23 | Oakley Andrew John | Director | Grant / award | 1,709 | $0.00 |
| 2024-12-20 | Schiess Ralph | Interim CEO, CSO | Grant / award | 177,462 | $0.00 |
| 2024-12-20 | Bruhlmann Christian | Chief Strategy Officer | Grant / award | 177,462 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:41 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-14 | 8-K | 2026-09-11 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-05-19 | 8-K | 2026-05-19 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-13 | View on SEC.gov → |
| 2026-05-13 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-04 | 8-K | 2026-04-30 | View on SEC.gov → |
| 2026-04-24 | 8-K | 2026-04-20 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-14 | View on SEC.gov → |
| 2026-04-21 | 4 | 2026-04-14 | View on SEC.gov → |
| 2026-04-16 | 4 | 2026-04-14 | View on SEC.gov → |
| 2026-03-27 | 8-K | 2026-03-23 | View on SEC.gov → |
Recent news
Headlines about ONCO (Onconetix, Inc.). Links open the publisher — we don’t host full articles.
-
BioNTech (BNTX) Stock May Be Fully Valued Despite Fresh Oncology Data Preview
Yahoo Finance · 2026-10-22 -
Cencora to buy American Oncology Network in $2.4 billion deal
Reuters · 2026-10-21 -
Cencora stock: Cencora agrees to acquire oncology network. What it means for Cencora stock
AD HOC NEWS · 2026-10-21 -
Breast pain before periods: Oncologist explains if tenderness is normal and shares 7 warning signs | Health
Hindustan Times · 2026-10-21 -
How Cullinan Oncology Inc. (CGEM) Affects Rotational Strategy Timing
Stock Traders Daily · 2026-10-21 -
Onco-Innovations Bets on Cboe Sign-Off as Lab Bench Progress Meets Balance-Sheet Reality
AD HOC NEWS · 2026-10-21 -
Coherus schedules October 28 webcast for Coherus Oncology stock
AD HOC NEWS · 2026-10-20 -
UBS reaffirms USD 15 target for Kura Oncology stock
AD HOC NEWS · 2026-10-20
No headlines in this category right now — try “All”.